Multiple myeloma with acute light chain cast nephropathy
Nelson Leung1,2, S Vincent Rajkumar3
1Division of Hematology, Mayo Clinic, Rochester, MN, USA. leung.nelson@mayo.edu.
Blood Cancer Journal
|March 29, 2023
Summary
Light chain cast nephropathy (LCCN), a cause of kidney injury in multiple myeloma (MM), requires rapid treatment. This paper offers a treatment algorithm for MM patients with LCCN to improve renal function recovery and survival.
Area of Science:
- Nephrology
- Hematology
- Internal Medicine
Background:
- Light chain cast nephropathy (LCCN) is a primary cause of acute kidney injury (AKI) in multiple myeloma (MM) patients.
- LCCN is now classified as a myeloma-defining event, highlighting its significance in disease management.
- Despite advances with novel agents, short-term mortality in LCCN patients remains high, particularly if renal failure is not reversed.
Purpose of the Study:
- To present a treatment algorithm for multiple myeloma patients with biopsy-proven light chain cast nephropathy (LCCN).
- To guide the management of acute kidney injury (AKI) in MM patients where LCCN is confirmed or other causes are excluded.
- To prioritize clinical trial enrollment for eligible patients before implementing the outlined treatment strategy.
Main Methods:
- Development of a treatment algorithm based on available randomized trial data.
- Incorporation of non-randomized data and expert opinions for recommendations where trial data is lacking.
- Emphasis on rapid reduction of involved serum free light chains as a critical treatment goal.
Main Results:
- The proposed algorithm aims to facilitate rapid and significant reduction of serum free light chains.
- The strategy is designed to improve the likelihood of renal function recovery in patients with LCCN.
- Prioritizing clinical trials is recommended for optimal patient outcomes.
Conclusions:
- A structured treatment algorithm is crucial for managing multiple myeloma patients with light chain cast nephropathy (LCCN).
- Prompt reduction of serum free light chains is essential for reversing renal failure and improving prognosis.
- Enrollment in clinical trials should be considered the primary approach for patients with LCCN.
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
50
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
50
01:24Nephrotic Syndrome I : Introduction
12
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
12
01:28Chronic Kidney Disease III: Interprofessional Care
60
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
60
01:29Acute Kidney Injury II: Pathophysiology
37
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
37
01:29Acute Kidney Injury III: Clinical Manifestations
48
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
48
01:26Nephrotic Syndrome II : Assessment and Medical Management
11
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
11